Genmab A (GMAB) Long-Term Investments (2018 - 2026)

Genmab A (GMAB) has reported Long-Term Investments for 9 consecutive years, with $36.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Investments rose 2.86% year-over-year to $36.0 million; the trailing twelve-month figure through Jun 2026 stood at $36.0 million (up 2.86% YoY), and the FY2025 full-year result was $37.0 million, up 15.62% from the prior year.
• Long-Term Investments declined to $36.0 million in Q2 2026 per GMAB's latest filing, from $40.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $261.8 million in Q4 2022 and bottomed at $12.6 million in Q4 2023.
• Historically, Long-Term Investments has averaged $35.9 million across 5 years, with a median of $19.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments plunged 95.19% in 2023, then soared 125.95% in 2025.
• Over 5 years, Long-Term Investments stood at $261.8 million in 2022, then slumped by 95.19% to $12.6 million in 2023, then jumped by 30.08% to $16.4 million in 2024, then jumped by 125.95% to $37.0 million in 2025, then slipped by 2.7% to $36.0 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $36.0 million, $40.0 million, and $37.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.